Clinical Trial Update: Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure [Phase 3]

View source ↗

Summary

Phase 3 trial comparing HS-20093 to Gemcitabine plus Docetaxel for osteosarcoma after second-line failure. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)
• HS-20093

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Osteosarcoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING